Cebiotex

cebiotex.com ↗ ·Barcelona ·Series A

Cebiotex is a Barcelona-based, Phase 2 clinical-stage biotechnology company that develops implantable, biodegradable nanofiber membranes for the local, sustained release of anti-tumor drugs directly at surgical resection sites, aiming to reduce cancer recurrence. Its lead candidate, CEB-01 (loaded with SN-38), has received EMA Orphan Drug Designation for pancreatic cancer and has been used in first-in-human studies in retroperitoneal sarcoma. Founded in 2012 as a spin-off of UPC and Hospital Sant Joan de Déu Barcelona; Joan Torrejon was appointed CEO in October 2025, with co-founder Joan Bertran moving to Chairman of the Board.

Founded

2012

Founders

Total funds raised

€4.5M

SectorsBiotechnology, Oncology, Medical Devices, Drug Delivery Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Joan Bertran

Co-Founder & Chairman of the Board (former CEO)

Jose Antonio Tornero

Co-Founder & Chief Technology Officer

Global models 5

TARIS Biomedical

United States · www.tarisbiomedical.com ↗

Developed an implantable local sustained drug-delivery system placed directly at the tumor site (bladder cancer), the closest analog to Cebiotex's implant-based local oncology drug delivery model; acquired by Johnson & Johnson.

$125.5MComparable

Instylla

United States · instylla.com ↗

Makes hydrogel-based embolic/local delivery devices administered directly into tumor vasculature for interventional oncology, matching Cebiotex's local (rather than systemic) tumor-site treatment approach.

$85MComparable

Nanobiotix

France · www.nanobiotix.com ↗

European clinical-stage oncology company using nanoparticle technology administered directly into or near tumors to enhance local cancer treatment, similar to Cebiotex's localized nanotechnology-based oncology approach.

$300M+ (incl. IPO and follow-ons)Comparable

Advanced Chemotherapy Technologies

United States · www.actbiotech.com ↗

Backed by Khosla Ventures, develops an implantable local chemotherapy delivery device for pancreatic cancer placed at the tumor site, closely mirroring Cebiotex's local post-surgical oncology drug delivery model.

$8MComparable

Everfront Biotech

Taiwan · www.efbiotech.com ↗

Developer of the Cerebraca Wafer, a biodegradable drug-eluting implant placed in the tumor resection cavity after glioma surgery to prevent recurrence, functionally the same model as Cebiotex's CEB-01 membrane.

$40M+Comparable

In the same niche 67 others

See all in the Start-ups Map →

Highlight Therapeutics

+61 more →

Notes: Most funded first

Investors 5

Open as list →

Capital Cell

capitalcell.com

3 rounds · 2015–21 Spain

Inveready

inveready.com

Seed 2017 Spain

Criteria Capital Risc

www.caixacapitalrisc.es

Ship2B Foundation

Seed 2017 Spain

Funding rounds 3

Date	Round	Amount	Lead
2021-02-25	Series A	€2.2M	Lead not disclosed +1 more
2017-02-23	Seed (estimated)	€1.8M	Lead not disclosed +3 more
2015-02	Seed	€500K	Lead not disclosed +1 more

News 5

Open as list →

Published	Article
2026-05-07	Cebiotex appoints Joan Torrejon as new CEO: "You can never give up" ↗ Tech Barcelona 2026-05-07
2025-11-03	La catalana Cebiotex abre una ronda de siete millones para impulsar su terapia oncológica ↗ The Objective 2025-11-03
2025-01-21	CEB-01 by Cebiotex for Pleomorphic Liposarcoma: Likelihood of Approval ↗ Pharmaceutical Technology 2025-01-21
2024-12-30	CEB-01 by Cebiotex for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval ↗ Pharmaceutical Technology 2024-12-30
2023-08-30	Cebiotex busca nuevo inversor para su patente oncológica y apunta a Estados Unidos y China ↗ PlantaDoce 2023-08-30